

Gabriel Pardo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3452307/publications.pdf>

Version: 2024-02-01

38
papers

1,199
citations

430442

18
h-index

377514

34
g-index

39
all docs

39
docs citations

39
times ranked

1845
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. <i>Lancet Neurology</i> , The, 2018, 17, 405-415.	4.9	238
2	Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , The, 2019, 18, 845-856.	4.9	110
3	The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. <i>Journal of Neurology</i> , 2017, 264, 2351-2374.	1.8	82
4	Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2014, 341, 22-27.	0.3	69
5	Safety and immunogenicity of a new formulation of interferon \hat{I}^2 -1a (Rebif \hat{A} [®] New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. <i>Multiple Sclerosis Journal</i> , 2009, 15, 219-228.	1.4	67
6	IFN- \hat{I}^2 Treatment Requires B Cells for Efficacy in Neuroautoimmunity. <i>Journal of Immunology</i> , 2015, 194, 2110-2116.	0.4	64
7	Retinal changes associated with tamoxifen treatment for breast cancer. <i>Eye</i> , 1997, 11, 295-297.	1.1	56
8	Reduced retinal nerve fiber layer and macular thickness in patients with multiple sclerosis with no history of optic neuritis identified by the use of spectral domain high-definition optical coherence tomography. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 1469-1472.	0.8	47
9	Decreased postural balance in multiple sclerosis patients with low disability. <i>International Journal of Rehabilitation Research</i> , 2011, 34, 53-58.	0.7	47
10	Epstein Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model. <i>Journal of Autoimmunity</i> , 2020, 106, 102332.	3.0	44
11	Immunogenicity and tolerability of an investigational formulation of interferon- \hat{I}^2 1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. <i>Clinical Therapeutics</i> , 2007, 29, 1128-1145.	1.1	38
12	Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. <i>Journal of Neurology</i> , 2020, 267, 3343-3353.	1.8	34
13	Assessment of Postural Balance in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2009, 11, 1-5.	0.4	34
14	Chiasmal trauma: Clinical and imaging considerations. <i>Survey of Ophthalmology</i> , 1994, 38, 381-383.	1.7	28
15	Headache and Its Management in Patients With Multiple Sclerosis. <i>Current Treatment Options in Neurology</i> , 2018, 20, 10.	0.7	25
16	A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis. <i>Journal of Neurology</i> , 2011, 258, 402-411.	1.8	24
17	Telerehabilitation in Multiple Sclerosis: Results of a Randomized Feasibility and Efficacy Pilot Study. <i>International Journal of Telerehabilitation</i> , 2018, 10, 55-64.	0.7	22
18	Nutrition and Optic Nerve Disease. <i>Seminars in Ophthalmology</i> , 1995, 10, 195-202.	0.8	18

#	ARTICLE	IF	CITATIONS
19	Use of Accelerometers to Measure Real-Life Physical Activity in Ambulatory Individuals with Multiple Sclerosis. <i>International Journal of MS Care</i> , 2015, 17, 215-220.	0.4	18
20	Effect of Oral Antihistamine on Local Injection Site Reactions With Self-Administered Glatiramer Acetate. <i>Journal of Neuroscience Nursing</i> , 2010, 42, 40-46.	0.7	15
21	Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102454.	0.9	15
22	Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 87-94.	0.9	14
23	Acute and Chronic Effects of Whole-Body Vibration on Balance, Postural Stability, and Mobility in Women With Multiple Sclerosis. <i>Dose-Response</i> , 2018, 16, 155932581881657.	0.7	13
24	Arterial Compliance in Multiple Sclerosis: A Pilot Study. <i>Angiology</i> , 2010, 61, 31-36.	0.8	11
25	Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2015, 17, 138-145.	0.4	11
26	The Association Between Persistence and Adherence to Disease-Modifying Therapies and Healthcare Resource Utilization and Costs in Patients With Multiple Sclerosis. <i>Journal of Health Economics and Outcomes Research</i> , 2022, 9, 111-116.	0.6	10
27	Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 639-649.	0.5	9
28	Association of vitamin D deficiency with RNFL thickness in MS individuals without history of optic neuritis. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 489-493.	0.9	7
29	Dalfampridine Effects Beyond Walking Speed in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2015, 17, 275-283.	0.4	6
30	Relationship between soleus H-reflex asymmetry and postural control in multiple sclerosis. <i>Disability and Rehabilitation</i> , 2022, 44, 542-548.	0.9	5
31	Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis. <i>Neurology and Therapy</i> , 2022, 11, 337-351.	1.4	5
32	Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 711-715.	1.7	4
33	Evaluation of Power Production Asymmetry during Cycling in Persons with Multiple Sclerosis. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3445.	1.2	3
34	Outcome measures assisting treatment optimization in multiple sclerosis. <i>Journal of Neurology</i> , 2022, 269, 1282-1297.	1.8	2
35	Cataclysmically disseminating neurologic presentation in an immunosuppressed lupus patient. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e582.	3.1	1
36	Immediate Effect of a Service Dog on Walking Speed in Individuals with Multiple Sclerosis and Gait Dysfunction: A Pilot Study. <i>International Journal of MS Care</i> , 2017, 19, 40-41.	0.4	1

#	ARTICLE	IF	CITATIONS
37	Functional intermuscular reduction in spasticity for people with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732110615.	0.5	1
38	Abnormal Eye Movements Due to Radiographically Silent Ischaemia as a Presenting Sign of Antiphospholipid Syndrome. Neuro-Ophthalmology, 2008, 32, 87-92.	0.4	0